MedTrace Logo

Liver Ablative Radiotherapy Utilising Kilovoltage Intrafraction Monitoring (KIM)

NCT02984566 · Status: ACTIVE_NOT_RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 32

Last updated 2026-05-19

No results posted yet for this study

Summary

Primary and secondary liver cancer patients will receive liver SABR with or without KIM intervention.

Conditions

Interventions

DEVICE

Kilovoltage Intrafraction Monitoring

KIM is a novel intrafraction real-time tumour localization method. It involves a single gantry-mounted kV x-ray imager acquiring 2D projections of implanted fiducial markers. 3D positions are then reconstructed by maximum likelihood estimation of a 3D probability density function.

Sponsors & Collaborators

  • University of Sydney

    lead OTHER

Principal Investigators

  • Tim Wang, Dr · Westmead Hospital

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
85 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-14
Primary Completion
2026-07-31
Completion
2026-07-31

Countries

  • Australia

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02984566 on ClinicalTrials.gov